Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Wait Pausing Investments
Novo Nordisk
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Wait Pausing InvestmentsRevenue(RF), mln.USD
241
Assets(RF), mln.USD
202
Capital(RF), mln.USD
154
Glob.Revenue, mln.USD
25005
Staff(RF), 2021
635
Taxes(RF), mln.USD
16
The Company Statement
May 23, 2023
Suspend further marketing and clinical investment; pause new clinical trials and active enrollment but increased revenue in Russia in 2022 vs 2021.
| March 29, 2022 | https://www.novonordisk.com/news-and-media/critical-updates.html |
| March 29, 2022 | Novo Nordisk to stop supplies of diabetes drug Ozempic to Russia this year |
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner